{"meta":{"status":200,"messages":[],"pagination":{"max":1,"offset":0,"count":1,"total":1,"pageNum":1,"totalPages":1,"sort":null,"currentUrl":"https://api.digitalmedia.hhs.gov/api/v2/resources/media.json?offset=0&max=1&ignoreHiddenMedia=1&format=json&id=635&newUrlBase=http://www.cdc.gov/Features/GrandRounds","nextUrl":null,"previousUrl":null}},"results":[{"content":"\n
\n

CDC Public Health Grand Rounds

\n
\n
\n

\"CollageWatch CDC\u2019s Public Health Grand Rounds, \u201cPre-Exposure Prophylaxis (PrEP) for Prevention of HIV Infection,\u201d which will be held on May 20, at 1 p.m. (EST) at www.cdc.gov/cdcgrandrounds.

\n

Pre-Exposure Prophylaxis (PrEP) for Prevention of HIV Infection\"
Tuesday, May 20, 2014
1-2 p.m., EST

\n

Watch the live broadcast at either of the following links:

\n \n

An estimated 50,000 individuals become infected with the human immunodeficiency virus (HIV) in the United States annually. A new prevention strategy, Pre-exposure Prophylaxis (PrEP), is intended for high-risk populations to reduce their risk of becoming infected with HIV. PrEP includes daily medication and routine follow-up.

\n

When used consistently, PrEP is shown to reduce the risk of HIV infection. If delivered effectively and used in combination with other proven prevention methods, PrEP may play a significant role in helping to address the HIV epidemic in the United States.

\n

Please join us as we explore the opportunities for using PrEP as another tool to prevent the transmission of HIV and discuss the challenges to effective implementation that must be addressed to make PrEP a success.

\n

Future Grand Rounds topics include the Hepatitis C Virus: Looking Back to Look Forward and Public Health Approaches to Reduce U.S. Infant Mortality (Encore).

\n

Presented By:

\n

Walid Heneine, PhD
Surveillance, Antiretroviral Prophylaxis and Drug Resistance Team Lead
Division of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

\n

\"HIV Pre-exposure Prophylaxis (PrEP) Preclinical Research in Animal Models\"
Melanie Thompson, MD
Founder and Principal Investigator
AIDS Research Consortium of Atlanta

\n

\"Evolving Evidence from Clinical Trials of HIV Pre-Exposure Prophylaxis\"
Dawn Smith, MD, MS, MPH
Biomedical Interventions Activity Lead, Prevention with Negatives Team
Division of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

\n

\"Program and Policy Challenges for Delivery of PrEP\"
Facilitated By:
John Iskander, MD, MPH, Scientific Director, Public Health Grand Rounds
Phoebe Thorpe, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds
Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds

\n
\n \n
Syndicated Content Details:
Source URL: http://www.cdc.gov/Features/GrandRounds/index.html
Source Agency: Centers for Disease Control and Prevention (CDC)
Captured Date: 2013-12-11 21:36:18.0
","description":"Watch CDC\u2019s Public Health Grand Rounds, \u201cPre-Exposure Prophylaxis (PrEP) for Prevention of HIV Infection,\u201d which will be held on May 20, at 1 p.m. (EST) at www.cdc.gov/about/grand-rounds.","id":635,"mediaType":"Html","name":"\"Measuring Science Impact\" - CDC Public Health Grand Rounds | CDC Features","sourceUrl":"http://www.cdc.gov/Features/GrandRounds/index.html"}]}